Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Galecto, Inc. (GLTO) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/02/2023 8-K Quarterly results
09/26/2023 8-K Cost Associated with Exit or Disposal Activities, Departure of Directors or Certain Officers; Election of Directors; Appointm...
Docs: "Galecto Announces Plans to Explore Strategic Alternatives"
08/15/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis Announces next steps for clinical development plan in severe liver diseases Boston, MA, August 15, 2023 - Galecto, Inc. , a clinical-stage biotechnology company and world leader in galectin biology, focused on the development of novel treatments for fibrosis and cancer, today announced topline results from its Phase 2b GALACTIC-1 trial evaluating the safety and efficacy of inhaled GB0139 for the treatment of idiopathic pulmonary fibrosis . The GALACTIC-1 trial did not meet its primary endpoint of change from baseline in rate of decline in forced vital capacity . Based on the results of the GALACTIC-1 trial, Galecto plans to discontinue development of GB0139. Going f..."
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
01/06/2023 8-K Quarterly results
10/31/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Galecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLD’s The Liver Meeting® 2022 • Late-breaking oral and poster presentations include clinical and preclinical data related to GULLIVER-2 clinical trial • Galecto to host a webinar at 8:00 a.m. ET on Tuesday, November 8, 2022 to discuss expanded topline data and analysis"
09/29/2022 8-K Quarterly results
06/17/2022 8-K Quarterly results
02/09/2022 8-K Quarterly results
01/27/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Galecto Publishes Results Showing Safety and Efficacy of the GB0139 Inhaled Galectin-3 Inhibitor in Hospitalized COVID-19 Patients on Standard of Care Results Support Favorable Safety and Tolerability Profile and Target Engagement of GB0139 and Potential for GB0139 in Severe Lung Disease"
01/05/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Updated Corporate Presentation, dated January 2022"
07/06/2021 8-K Quarterly results
05/28/2021 8-K Quarterly results
03/15/2021 8-K Quarterly results
01/08/2021 8-K Quarterly results
01/05/2021 8-K Quarterly results
11/23/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Non-Employee Director Compensation Policy",
"Galecto Appoints Experienced Healthcare Executive Jayson Dallas to Board of Directors"
11/04/2020 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : November 2, 2020 GALECTO, INC. Delaware 001-39655 37-1957007 Ole Maaloes Vej 3 DK-2200 Copenhagen N Denmark 70 70 52 10 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 under t...",
"Amended and Restated Certificate of Incorporation of Galecto, Inc",
"Amended and Restated By-laws of Galecto, Inc"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy